Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 267-273

  Ziolkowska, Maria ^a   Maslinski, Wlodzimierz ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; CASPASE 8; CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD32 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; CHIMERIC ANTIBODY; DNA ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; METHOTREXATE; PADGEM PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANEMIA; ANTIBODY DETECTION; BONE EROSION; BONE METABOLISM; BURST FORMING UNIT E; CARTILAGE DEGENERATION; CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DISEASE MARKER; DRUG MEGADOSE; DRUG SYNOVIAL FLUID LEVEL; ERYTHROID PRECURSOR CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; LABORATORY TEST; MEMORY CELL; NEUTROPHIL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038746746     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00014     Document Type: Review

References (49)

1. Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res 2002, 4(suppl 2):S22-S28.
2. Criscione LG, St Clair EW: Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002, 14:204-211.
3. Elson CO: Genes, microbes, and T cells: new therapeutic targets in Crohn's disease. N Engl J Med 2002, 346:614-616.
4. Lipsky PE, van der Heijde DMFM, Clair EWS, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
5. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
7. Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
8. Furst DE, Breedveld FC, Kalden JR, et al.: Updated consensus statement on biologic agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2002, 61(suppl 2):112-117.
9. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
10. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
11. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
12. Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther 2002, 4:185-190.
13. Scallon B, Cai A, Solowski N, et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-26. This in vitro study showed the structure-related differences between infliximab and etanercept in recognition and stability of their complexes with TNF-α. Interestingly, dissociated from etanercept, TNF-α was biologically active. If these properties of both drugs are retained in vivo, the results presented may have important consequences for the efficacy of TNF-α blockade.
14. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157. This study shows that monocytopenia often seen in patients treated with infliximab is related to the caspase-dependent monocyte apoptosis.
15. Barone D, Krantz C, Lambert D, et al.: Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum 1999, 42(suppl):S90.
16. ten Hove T, van Montfrans C, Peppelenbosch MP, et al.: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
17. Wagner CL, St Clair EW, Han C, et al.: Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT Study. Arthritis Rheum 2002, 46(suppl):S132.
18. Antivalle M, Marrazza MG, Randisi G, et al.: Long term treatment of rheumatoid arthritis with infliximab: efficacy, side effects, and autoantibodies induction. Arthritis Rheum 2002, 46(suppl):S534.
19. Charles PJ, Smeenk RJ, De Jong J, et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2390.
20. De Rycke L, Van Damme N, Kruithof E, et al.: Antinuclear antibody profile following infliximab treatment in rheumatoid arthritis and spondyloarthropathy. Arthritis Rheum 2002, 46(suppl):S128.
21. Jonsdottir T, Harju A, van Vollenhoven A, et al.: Treatment with TNF-antagonists is associated with an increasing frequency of anticardiolipin antibodies (ACLA): ACLA positivity predicts worse clinical outcomes. Arthritis Rheum 2002, 46(suppl):S573.
22. Ferraccioli G, Mecchia F, Di Poi E, et al.: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002, 61:358-361.
23. Charles P, Elliott MJ, Davis D, et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
24. Markham A, Lamb HM: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000, 56:1341-1359.
25. Moreland LW, Bucy RP, Weinblatt ME, et al.: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002, 103:13-21.
26. Kavanaugh AF, Greenwald M, Zizic T, et al.: Treatment with adalimumab (D2E7) does not affect normal immune responsiveness. Arthritis Rheum 2002, 46(suppl):S132.
27. Pittoni V, Bombardieri M, Spinelli FR, et al.: Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002, 61:723-725. This study indicates that at least in RA patients, the induction of IL-18 is TNF-α dependent.
28. Tokayer A, Carsons SE, Chokshi B, et al.: High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. J Rheumatol 2002, 29:454-461. This study shows that high levels of biologically active IL-13 at baseline is decreased in serum of etanercept treated RA patients.
29. Drynda S, Kuhne C, Kekow J: Soluble tumor necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis 2002, 61:254-256. This is the first indication that enhanced levels of transforming growth factor in RA patients does not depend on TNF-α.
30. Ziolkowska M, Kurowska M, Radzikowska A, et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753. An important paper describing normalization of high serum levels of two key factors affecting bone metabolism, osteoprotegerin and receptor activator of nuclear factor kappa B ligand, on treatment of RA patients with infliximab. These results indicate the mechanism that may be responsible for enhanced bone erosion seen in RA patients.
31. Catrina AI, Lampa J, Ernestam S, et al.: Anti-tumor necrosis factor (TNF)-alpha therapy (etanercept) downregulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002, 41:484-489.
32. Brennan FM, Browne KA, Green PA, et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997, 36:643-650.
33. den Broeder AA, Joosten LA, Saxne T, et al.: Long term anti-tumor necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiologic course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002, 61:311-3118. The results of this study suggest that baseline serum levels of soluble intercellular adhesion molecule (sICAM) and cartilage oligomeric matrix protein may be helpful to identify patients with progressive and nonprogressive radiologic outcome.
34. Paleolog EM, Hunt M, Elliott MJ, et al.: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:1082-1091.
35. Lorenz HM, Antoni C, Valerius T, et al.: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996, 156:1646-1653.
36. Lorenz HM, Grunke M, Hieronymus T, et al.: In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: long-term effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol 2000, 27:304-310.
37. Voskuyl AE, Scheffer PG, Heijst JA, et al.: Changes in lipid profile of patients with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002, 46(suppl):S510.
38. Straub RH, Pongratz G, Scholmerich J, et al.: Recurring anti-TNF antibody therapy repeatedly decreases serum levels of interleukin-6 (IL-6), cortisol, and the ratio of cortisol/17-hydroxyprogesterone in rheumatoid arthritis (RA). Arthritis Rheum 2002, 46(suppl):S131.
39. Familian A: Course of pentraxin-mediated complement activation in RA patients upon treatment with infliximab. Arthritis Rheum 2002, 46(suppl):S137.
40. Goldbach-Mansky RT, Souto-Carneiro MM, Mahadevan V, et al.: TNF blockade results in an increase of CD20+CD27+ (memory) B cells in the peripheral circulation of rheumatoid arthritis (RA) patients. Arthritis Rheum 2002, 46(suppl):S505.
41. Papadaki HA, Kritikos HD, Valatas V, et al.: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002, 100:474-482. This is an elegant study demonstrating that anemia of chronic disease in rheumatoid arthritis is associated with TNF-α dependent enhancement of bone marrow erythroid cells precursors apoptosis.
42. Gravallese EM: Bone destruction in arthritis. Ann Rheum Dis 2002, 61(suppl 2):1184-1186.
43. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFκB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
44. Genovese MC, Bathon JM, Martin RW, et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
45. Lampa J, van Vollenhoven RF, Klareskog L, et al.: Association between IL10 gene polymorphism and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2002, 46(suppl):S136.
46. Voll RE, Hantschel M, Dechant C, et al.: Decrease of the NF-kappa B DNA-binding activity in peripheral blood mononuclear cells by treatment of rheumatoid arthritis patients with anti-TNF antibody infliximab. Ann Rheum Dis 2002, 61(suppl 1):265.
47. Marotte H, Miossec P: Function of circulating TNF in rheumatoid arthritis patients with infliximab: link to clinical response. Arthritis Rheum 2002, 46(suppl):S254.
48. St Clair EW, Wagner CL, Fasanmade AA, et al.: The relation of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459. This paper describes the association between higher serum levels of infliximab with increased ACR 20 response, greater reduction in C-reactive protein and less progression of radiographic joint damage in RA patients from ATTRACT trial. These results suggest that some patients, with lower/undetectable levels of serum infliximab may benefit from higher dose of the drug.
49. Ziolkowska M, Wiland P, Szechinski J, et al.: DAS28 and decrease of serum osteoprotegerin from baseline level represent parameters predicting long-term efficacy of infliximab plus methotrexate treatment in rheumatoid arthritis patients. Arthritis Rheum 2002, 46(suppl):S135.